USRE38623E1 - Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use - Google Patents

Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use Download PDF

Info

Publication number
USRE38623E1
USRE38623E1 US09/725,980 US72598000A USRE38623E US RE38623 E1 USRE38623 E1 US RE38623E1 US 72598000 A US72598000 A US 72598000A US RE38623 E USRE38623 E US RE38623E
Authority
US
United States
Prior art keywords
composition
ascorbic acid
substantially anhydrous
base comprises
anhydrous base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/725,980
Inventor
Steven Hernandez
Burt Shaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topix Pharmaceuticals Inc
Original Assignee
Topix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topix Pharmaceuticals Inc filed Critical Topix Pharmaceuticals Inc
Priority to US09/725,980 priority Critical patent/USRE38623E1/en
Application granted granted Critical
Publication of USRE38623E1 publication Critical patent/USRE38623E1/en
Assigned to TOPIX PHARMACEUTICALS INC. reassignment TOPIX PHARMACEUTICALS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERNANDEZ, STEVEN, SHAFFER, BURT
Anticipated expiration legal-status Critical
Assigned to ARES CAPITAL CORPORATION reassignment ARES CAPITAL CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOPIX PHARMACEUTICALS INC.
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients
    • A61K2800/31Anhydrous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers

Definitions

  • Oxy-radicals in Molecular Biology and Pathology (Alan Liss, publisher, New York, N.Y. 1988). Hayaishi, O. et al. eds., Biological Role of Reactive Oxygen Species in Skin, (Elsevier Press, New York, N.Y. 1987). Johnson Jr., J. E. et al. eds., Free Radicals, Aging and Degenerative Diseases, (Alan Liss publisher, New York, N.Y. 1986). Halliwell, B. et al. eds. Free Radicals in Biology and Medicine, (Clarendon Press, Oxford, U.K. 1985), and Sied, H., ed., Oxidative Stress, (Academic Press, 1985), among other cited publications therein.
  • ascorbic acid such as Vitamin C
  • Ascorbic acid loses potency and discolors easily in most delivery vehicles.
  • Ascorbic acid hydrolyzes when exposed to water.
  • stable is defined as a characteristic wherein a composition retains potency for the duration of a predetermined expiration period, as defined by generally accepted pharmaceutical protocols, such as “GMP”, or “good manufacturing practices” as promulgated by various trade conventions, such as for example, the United States Pharmaceutical (USP) convention.
  • GMP generally accepted pharmaceutical protocols
  • USP United States Pharmaceutical
  • the carrier is described as being compatible with water, preferably distilled or deionized water without contaminants, which further de-stabilize ascorbic acid.
  • a method of preventing and/or treating photo-aged skin, sunburn, wrinkles and related skin disorders is provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a substantially anhydrous composition, with no water added, containing effective amounts of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin.
  • the composition of the present invention can also be used to prevent photo-aging of the skin.
  • the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid are provided in a substantially anhydrous base, with no added water. Because the components have a natural water sub-component, the base is not water free, but is substantially anhydrous, because the pre-existing water concentration does not generally exceed five (5) percent by weight of the total composition. To achieve the substantially anhydrous composition, no water is added, in contrast to the water-based composition in Darr '043.
  • the substantially anhydrous composition includes silicones and derivatives of silicone chemistry.
  • other substantially anhydrous composition, with no water added may be utilized, such as other emollients, emulsifiers, surfactants, oils and waxes, polyols, binders, anti-oxidants or chelating agents.
  • inactive components may include preservatives, humectants, viscosity control aids, pH buffers and carrier solvents.
  • pH buffers and solvents may also function as a substantially anhydrous base.
  • a method of treating photo-aged skin, sunburn, wrinkles and related skin disorders is also provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a substantially anhydrous composition, with no water added, containing effective amounts of a compound selected from the group consisting of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin.
  • the compound containing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid is provided in a substantially anhydrous with no water added base without water.
  • the base provides a unique cosmetically elegant topical vehicle which protects the ascorbic acid or its derivatives from degradation, instability, loss of potency and loss of color.
  • the base includes a mixture of a substantially anhydrous composition, with no water added, with the compound, wherein the substantially anhydrous composition is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30 percent.
  • topically applied skin care products which can be prepared using conventional procedures from the following ingredients with typical ranges of acceptable percentages by weight and typical preferred percentage by weight shown.
  • the formulations are illustrative only:
  • the present invention therefore includes a method for the prevention and/or treatment of photo-aged skin and related skin disorders, such as wrinkles, sunburn, poor skin tone and skin discoloration.
  • topical applications are applied periodically such as one or two times per day.
  • Table 1 shows the stability of examples of the composition. Stability tests were conducted of topical skin treatment compositions containing ascorbic acid, specifically L-ascorbic acid at 10%. The compositions were tested for percentage of stability as a function of shelf life in a closed jar at either room temperature or at an elevated temperature of from 40° C. to 45° C. Tests of the containers of the compositions at room temperature were conducted over a six month period and tests of the containers of the compositions at elevated temperature of from 40° C. to 45° C. were conducted over a three month period.

Abstract

A stable composition is provided to treat and/or prevent photo-aged skin and related skin disorders such as sunburn, wrinkles, poor skin tone and skin discoloration by topically applying to the skin the treatment composition containing an effective amount of a compound such as ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, in a pharmaceutically acceptable vehicle containing a substantially anhydrous base having no water added. The anhydrous base stabilizes the compound, so that the compound remains effective for an effective period of time, even in the presence of exposure to water.

Description

This application is based upon provisional application Ser. No. 60/011,441, filed Feb. 9, 1996.
FIELD OF THE INVENTION
The present invention is directed to a composition for stabilizing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a stable delivery system for topical application to the skin. The composition prevents premature aging of the skin of humans, or may be used to treat photo-aged skin and resultant wrinkles and other sequelae.
BACKGROUND OF THE INVENTION
Treatment of photo-aged skin and resultant wrinkles and other sequelae with ascorbic acid and related derivatives has been discussed in the prior art. Among the most common treatment regimen is a topical application of ascorbic acid to affected areas of the skin in lotions, creams and other delivery vehicles, such as discussed in U.S. Pat. No. 5,140,043 of Darr et al for stable ascorbic acid compositions.
In Darr '043, it is noted that L-ascorbic acid prevents ultraviolet (UV) damage to the skin. In the discussion of the background art therein. Darr '043 states that ascorbic acid, also commonly known as Vitamin C, acts as an anti-oxidant to counteract the skin damaging effects of superoxide and hydroxyl radicals, which have been known to cause a wide variety of damaged skin conditions ranging from transitory sunburn to permanent wrinkles from photo-aged skin. According to Darr '043, these radicals destroy lipid membranes, break down DNA and inactivate beneficial enzymes which promote healthy skin conditions, citing Cerutti, D. et al. eds. Oxy-radicals in Molecular Biology and Pathology, (Alan Liss, publisher, New York, N.Y. 1988). Hayaishi, O. et al. eds., Biological Role of Reactive Oxygen Species in Skin, (Elsevier Press, New York, N.Y. 1987). Johnson Jr., J. E. et al. eds., Free Radicals, Aging and Degenerative Diseases, (Alan Liss publisher, New York, N.Y. 1986). Halliwell, B. et al. eds. Free Radicals in Biology and Medicine, (Clarendon Press, Oxford, U.K. 1985), and Sied, H., ed., Oxidative Stress, (Academic Press, 1985), among other cited publications therein.
Free radicals from ultraviolet light (UV) are known to increase with air pollution in areas of concentrated populations, thereby magnifying the problem. The free radicals are destructive in that the free radicals hydrolyse elastin fibers in the skin and desynthesize collagen in the lower dermal layers of the skin, thereby causing skin wrinkles and other damaging skin conditions.
In contrast, it has also been known that ascorbic acid is effective in counteracting the effects of free radicals upon the skin. Ascorbic acid absorbs ultraviolet (UV) radiation and at the same time stimulates collagen production.
However, ascorbic acid, such as Vitamin C, is difficult to stabilize for any significant period of time in pharmaceutical vehicles for topical delivery to the skin. Ascorbic acid loses potency and discolors easily in most delivery vehicles. Furthermore, ascorbic acid hydrolyzes when exposed to water.
The term “stable” is defined as a characteristic wherein a composition retains potency for the duration of a predetermined expiration period, as defined by generally accepted pharmaceutical protocols, such as “GMP”, or “good manufacturing practices” as promulgated by various trade conventions, such as for example, the United States Pharmaceutical (USP) convention.
For example, for a topically applied skin care formulation, the expected duration of a predetermined expiration period should be at least eight months before the formulation loses significant potency.
In contrast Dar '043 only tested the product described therein for twelve weeks.
Moreover, as noted in Darr '043, ascorbic acid washes off easily when exposed to water, so that topical application at a sun-lit beach is generally futile, since swimming washes away the topically applied ascorbic acid.
Furthermore, in the past, ascorbic acid has been administered in high dosages to the skin, and has to be made every day because of its instability, thus increasing cost of its use.
Darr '043 discloses a method of stabilizing ascorbic acid in a water based delivery system with an ascorbic acid to water/carrier ratio of at least 1:1, preferably 2:1 to 10:1.
The ascorbic acid and water mix described in Darr '043 includes both water and a carrier, such as alkylene glycols, or alkylene glycols in combination with one or more derivatives of hydroxyalkyl-cellulose. However, the minimum amount of water in the product disclosed in Darr '043 is fifty (50) percent, since Darr '043 teaches at least a 1:1 ratio of water to carrier, preferably greater than fifty (50) percent, such as sixty seven (67) percent water in a 2:1 ratio, up to ninety two (91) percent water in a 10:1 water/carrier ratio.
In general, the carrier is described as being compatible with water, preferably distilled or deionized water without contaminants, which further de-stabilize ascorbic acid.
However, the disadvantage of the delivery vehicle in Darr '043 is that it is water-based, and therefore the ascorbic acid is still inherently unstable.
For example, while FIG. 1 of Darr '043 shows small drops in potency of L-ascorbic acid of less than 10 percent over seven weeks at room temperature of L-ascorbic concentrations of three (3), five (5) and ten (10) percent respectively. FIG. 1 shows a drop in potency of approximately 30 percent over seven weeks, from 100 percent to 70 percent, of L-ascorbic acid in a concentration of one (1) percent.
Moreover, FIG. 2 of Darr '043 shows all four samples of L-ascorbic acid having lost potency of at least ten (10) percent over eight (8) weeks at room temperature, when stored under controlled conditions in the dark.
Furthermore, while the testing in Darr '043 was conducted from between seven (7) and twelve (12) weeks duration, any viable over the counter consumer product requires in excess of twelve weeks from manufacture through distribution points to final retail sale, and must still afford the consumer a reasonable time to consume the contents of the product. Therefore, a loss in potency of the magnitude as shown in Darr '043 in such a short time span, raises serious questions as to the usefulness of the stability data obtained in predicted the potency of L-ascorbic acid at the time the consumer is able to use the product.
Therefore, the response of the ascorbic acid in the epidermals and dermis of the skin is not very effective, because of the presence of substantial amounts of water, which contribute to destabilization of the ascorbic acid.
OBJECTS OF THE INVENTION
It is therefore an object of the present invention to provide a stable composition and pharmaceutical delivery system for ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid as effective treatments for photo-aged skin and related skin disorders.
It is yet another object to provide a topical preparation of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for more effective treatment of photo-aged skin and related skin disorders.
It is yet a further object to provide a topical delivery vehicle for ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, wherein the delivery vehicle is substantially anhydrous with no water added.
It is yet a further object to provide ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, in a composition wherein the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid remain effective for an extended period of time.
It is yet another object to improve over the disadvantages of the prior art.
BRIEF SUMMARY OF THE INVENTION
In keeping with these objects and others which may become apparent, according to the present invention, a new stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, to prevent and treat sun-damaged and photo-aged skin, and as a preventative and cosmetic for undamaged skin.
A method of preventing and/or treating photo-aged skin, sunburn, wrinkles and related skin disorders is provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a substantially anhydrous composition, with no water added, containing effective amounts of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin. The composition of the present invention can also be used to prevent photo-aging of the skin.
Ascorbic acid, or its derivatives, such as ascorbic palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate and related compounds, is applied in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a substantially water based delivery system, the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid are provided in a substantially anhydrous base, with no added water. Because the components have a natural water sub-component, the base is not water free, but is substantially anhydrous, because the pre-existing water concentration does not generally exceed five (5) percent by weight of the total composition. To achieve the substantially anhydrous composition, no water is added, in contrast to the water-based composition in Darr '043.
The substantially anhydrous base protects the ascorbic acid, or its derivatives and/or extracts containing ascorbic acid, from degradation, instability, loss of potency and loss of color.
The topical pharmaceutical delivery vehicle includes a mixture of a base consisting essentially of a substantially anhydrous composition, with no water added, in combination with the ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, wherein the substantially anhydrous composition, with no water added, is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30 percent by weight.
In the preferred embodiment, the substantially anhydrous base includes silicone compounds, which provide a unique, cosmetically elegant smooth, lustrous tactile feel when applied to the skin.
Preferably the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry. However, other substantially anhydrous composition, with no water added, may be utilized, such as other emollients, emulsifiers, surfactants, oils and waxes, polyols, binders, anti-oxidants or chelating agents.
Other inactive components may include preservatives, humectants, viscosity control aids, pH buffers and carrier solvents. However, certain pH buffers and solvents may also function as a substantially anhydrous base.
The resultant mixture is smooth feeling delivery vehicle which delivers the ascorbic acid or its derivatives to the skin in an effective and stable manner.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, a stable, long-lasting composition is provided as a pharmaceutical delivery vehicle for delivery of ascorbic acid to sun-damaged and photo-aged skin.
A method of treating photo-aged skin, sunburn, wrinkles and related skin disorders is also provided by topical application of a lotion, cream, gel or pad applied formulation, preferably a substantially anhydrous composition, with no water added, containing effective amounts of a compound selected from the group consisting of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, for topical application to the affected area of the skin.
Ascorbic acid, or its derivatives, such as ascorbyl palmitate, sodium ascorbate, potassium ascorbate, ammonium ascorbate, triethanolamine ascorbate, ascorbyl phosphate or magnesium ascorbyl phosphate, ascorbic acid polypeptides, ascorbyl glucosamine, ascorbic acid polymers, esters of ascorbic acid, amides of ascorbic acid L-ascorbic acid, known as vitamin C, or other derivatives, or related compounds, including botanical or herbal extracts, such as extracts of acerola, citrus extracts, strawberry, which may supply L-ascorbic acid or its derivatives, is applied in a pharmaceutically acceptable vehicle, in a concentration of from 0.1 percent by weight to 95 percent by weight, preferably 10-15 percent by weight, generally by frequent periodic application, such as by a once or twice daily application.
Instead of a water based delivery system, the compound containing ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid, is provided in a substantially anhydrous with no water added base without water. The base provides a unique cosmetically elegant topical vehicle which protects the ascorbic acid or its derivatives from degradation, instability, loss of potency and loss of color. The base includes a mixture of a substantially anhydrous composition, with no water added, with the compound, wherein the substantially anhydrous composition is provided in a range of from 0.1 percent by weight to 99.8 percent by weight, preferably about 30 percent.
Preferably, the substantially anhydrous composition, with no water added, includes silicones and derivatives of silicone chemistry, including but not limited to cyclomethicones (volatile silicones), linear silicones, dimethylpolysiloxane, dimethicone copolyols, silicone glycols, aminofunctional silicones, polymeric silicones, silicone waxes, such as high molecular weight dimethicones and silicone derivative waxes.
When various silicone compounds are used, a lustrous, elegant smooth tactile feel is achieved when the topical composition is applied to the skin.
Other substantially anhydrous compositions, with no water added, may be substituted for the silicones, such as other emollients, including but not limited to esters, amides, ethoxylated fats, mineral oil, petrolatum, vegetable fats and animal fats, such as hydrogenated tallow and lanolin.
Substantially anhydrous synthetic waxes, such as triglycerides and tribehin may be utilized. Polyols such as polyhydric alcohols and solvent such as mineral oil, glycerin and propylene glycol and sorbitol may be used.
Emulsifiers such as anhydrous polysorbate and PEG 60 hydrogenated castor oil may be employed, as well as anhydrous surfactants such as nonphenol.
Anti-oxidants, such as BHA, BHT, propylgallate, Vitamin E tocopherol, as well as chelating agents such as disodium EDTA, may also be used to further stabilize other substantially anhydrous bases. However, liquid or non-granular anti-oxidants, may be used as a substantially anhydrous base with ascorbic acid by themselves.
Fat soluble vitamins, such as substantially anhydrous Vitamins A, D and E and their esters or derivatives, may also be used as bases for the ascorbic acid based composition.
Moreover, pH buffers such as alkaline sodium citrate and magnesium citrate are effective as substantially anhydrous bases for the delivery vehicle.
Other inactive components may include preservatives, humectants, viscosity control aids, pH buffers and carrier solvents. However, as noted above, certain pH buffers and solvents may also act as an anhydrous base.
The resultant mixture is a comfortable delivery vehicle which delivers the ascorbic acid, its derivatives or extracts containing ascorbic acid to the skin in an effective and stable manner.
The following examples illustrate topically applied skin care products which can be prepared using conventional procedures from the following ingredients with typical ranges of acceptable percentages by weight and typical preferred percentage by weight shown. The formulations are illustrative only:
Ingredient Range(% w/w) Preferred(% w/w)
Formulation #1:
Ascorbic acid 0.1-95.0 10.0
Cyclomethicone 0.1-99.8 30.0
Water (no water added)   0-5.0  0.0
Surfactant   0-90.0 5.0
Methylparaben (preservative) 0.0-3.0  0.2
Steareth-2 (emulsifier) 0.0-10.0 3.5
Gelene (viscosity aid) 0.0-95.0 36.3
Bentronite (binder) 0.0-25.0 5.0
Formulation #2:
Polyglyceryl methacrylate Gel 0.0-99.0 60.0
Ascorbic acid 0.1-95.0 15.0
Silicone Glycol 0.1-60.0 15.0
Water 0.0 0.0
The present invention therefore includes a method for the prevention and/or treatment of photo-aged skin and related skin disorders, such as wrinkles, sunburn, poor skin tone and skin discoloration.
The method comprises steps of the topical application of suitable compositions containing ascorbic acid, its derivatives or extracts containing ascorbic acid, in a substantially anhydrous base, with no water added.
In general, the treatment composition suitable for use in accordance with the invention containing ascorbic acid, its derivatives or extracts containing ascorbic acid, may be applied in any dermatological acceptable vehicle such as a gel, lotion, cream or pad applied formulation, which may or may not be emulsified and may contain ingredients to improve, modify, or stabilize the formulation physically or cosmetically. Other suitable formulations will be apparent to those skilled in the art.
The treatment compositions of the invention will improve the condition of the skin to which it is applied, preferably by frequent periodical application over an extended period of time without undue irritation to the skin or any other side effects.
Generally, the topical applications are applied periodically such as one or two times per day.
Moreover, Table 1 shows the stability of examples of the composition. Stability tests were conducted of topical skin treatment compositions containing ascorbic acid, specifically L-ascorbic acid at 10%. The compositions were tested for percentage of stability as a function of shelf life in a closed jar at either room temperature or at an elevated temperature of from 40° C. to 45° C. Tests of the containers of the compositions at room temperature were conducted over a six month period and tests of the containers of the compositions at elevated temperature of from 40° C. to 45° C. were conducted over a three month period.
TABLE I
Composition No. 1:
a topical facial complex containing 10% of L-ascorbic acid.
a) Condition: maintained at room temperature in a ½ oz.
clear jar with lined cap.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 80.0%-110.0%
d) Resultant Percentage of Stability:
0 months 3 months 6 months
95.6% 90.1% 90.4%
Composition No. 1:
a topical facial complex containing 10% of L-ascorbic acid.
a) Condition: maintained at 40° C. to 45° C. in a
½ oz. clear jar with lined cap.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 90.0%-110.0%
d) Resultant Percentage of Stability:
0 months 1 month 2 months 3 months
95.6% 91.4% 90.4% 84.5%
Composition No. 2:
a topical hand and body complex containing 10% of
L-ascorbic acid.
a) Condition: maintained at room temperature in a 2 oz.
container.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 80.0%-110.0%
d) Resultant Percentage of Stability:
0 months 3 months 6 months
98.5% 92.4% 90.2%
Composition No. 2:
a topical hand and body complex containing 10% of
L-ascorbic acid.
a) Condition: maintained at eleveated temperature from
40° C. to 45° C. in a 2 oz. container.
b) Test: ascorbic acid assay.
c) Recommended Percentage of Stability: 80.0%-110.0%
d) Resultant Percentage of Stability:
0 months 1 month 2 month 3 months
98.5% 95.0% 91.1% 84.0%
Other changes to the present invention may be made without departing from the spirit or scope thereof, when read in conjunction with the appended claims.

Claims (21)

We claim:
1. A topical composition consistently essentially of a mixture of a compound selected from the group consisting of ascorbic acid, derivatives of ascorbic acid and extracts containing ascorbic acid and a substantially anhydrous pharmaceutically acceptable base in an amount of above about 10% by weight of the composition.
2. The composition as in claim 1 wherein said substantially anhydrous base comprises a silicone.
3. The composition as in claim 2 wherein said substantially anhydrous base comprises a cyclomethicone.
4. The composition as in claim 2 wherein said substantially anhydrous base comprises a linear silicone.
5. The composition as in claim 2 wherein said substantially anhydrous base comprises dimethylpolysiloxane.
6. The composition as in claim 2 wherein said substantially anhydrous base comprises a dimethicone copolyol.
7. The composition as in claim 2 wherein said substantially anhydrous base comprises a silicone glycol.
8. The composition as in claim 2 wherein said substantially anhydrous base comprises an aminofunctional silicone.
9. The composition as in claim 2 wherein said substantially anhydrous base comprises an polymeric silicone.
10. The composition as in claim 1 wherein said substantially anhydrous base comprises an emollient.
11. The composition as in claim 1 wherein said substantially anhydrous base comprises an emulsifier.
12. The composition as in claim 1 wherein said substantially anhydrous base comprises a surfactant.
13. The composition as in claim 1 wherein said substantially anhydrous base comprise a liquid anti-oxidant.
14. The composition as in claim 1 wherein said substantially anhydrous base comprises as chelating agent.
15. The composition as in claim 1 wherein said substantially anhydrous base comprises a solvent.
16. The composition as in claim 1 wherein said substantially anhydrous base comprises a synthetic wax.
17. The composition as in claim 1 wherein said substantially anhydrous base comprises an alkaline anhydrous pH buffer.
18. The composition as in claim 1 wherein said substantially anhydrous base comprises a fat soluble vitamin.
19. The method of treating photo-aged skin and related skin disorders, wrinkles, sunburn, poor skin tone and/or skin discoloration, comprising the steps of applying topically to the area of the skin affected an effective amount of a treatment composition consistently essentially of a mixture of a compound selected from the group consisting of ascorbic acid, derivatives of ascorbic acid and extracts containing ascorbic acid and a pharmaceutically acceptable vehicle comprising a substantially anhydrous single phase carrier base, said compound being present in an amount of above about 10 percent by weight of the treatment composition.
20. The method according to claim 19, wherein said treatment composition is applied periodically to the skin area to be treated, said periodic treatment being applied in an amount as required to be efficacious.
21. The method according to claim 19, wherein said pharmaceutically acceptable vehicle including the substantially anhydrous base is provided in the group consisting of a cream, lotion, pad applied formulation of gel base.
US09/725,980 1996-02-09 2000-11-29 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use Expired - Lifetime USRE38623E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/725,980 USRE38623E1 (en) 1996-02-09 2000-11-29 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1144196P 1996-02-09 1996-02-09
US08/796,784 US5843411A (en) 1997-02-06 1997-02-06 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
KR1019980043559A KR20000026159A (en) 1997-02-06 1998-10-15 Method for stabilizing an ascorbic acid, its derivatives and/or extract containing ascorbic acid for local application
CA002251414A CA2251414A1 (en) 1997-02-06 1998-10-16 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
AU89455/98A AU8945598A (en) 1997-02-06 1998-10-21 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts con taining ascorbic acid for topical use
US09/725,980 USRE38623E1 (en) 1996-02-09 2000-11-29 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/796,784 Reissue US5843411A (en) 1996-02-09 1997-02-06 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Publications (1)

Publication Number Publication Date
USRE38623E1 true USRE38623E1 (en) 2004-10-12

Family

ID=31999271

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/796,784 Ceased US5843411A (en) 1996-02-09 1997-02-06 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US09/725,980 Expired - Lifetime USRE38623E1 (en) 1996-02-09 2000-11-29 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/796,784 Ceased US5843411A (en) 1996-02-09 1997-02-06 Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Country Status (4)

Country Link
US (2) US5843411A (en)
KR (1) KR20000026159A (en)
AU (1) AU8945598A (en)
CA (1) CA2251414A1 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077261A1 (en) * 2005-10-03 2007-04-05 Jerry Zhang Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers
US20080292668A1 (en) * 2005-07-08 2008-11-27 Beatrice Baars Water-Free Cosmetic Preparation
US20080312169A1 (en) * 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090197819A1 (en) * 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
US20090232750A1 (en) * 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8760906B2 (en) 2009-11-24 2014-06-24 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor memory device
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2014188276A2 (en) 2013-04-22 2014-11-27 Neocutis Sa Antioxidant compositions and methods of using the same
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US20180071205A1 (en) * 2014-12-08 2018-03-15 Jeane Disalvo Stable Vitamin C System
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194452B1 (en) 1997-11-07 2001-02-27 Howard Murad Stable pharmaceutical compositions including ascorbic acid and methods of using same
US6110966A (en) * 1998-02-20 2000-08-29 Medi-Cell Laboratories, Inc. Triple action complex
IL138146A0 (en) * 1998-03-12 2001-10-31 Procter & Gamble Disposable absorbent article having a skin care composition containing an enzyme inhibitor
US6146664A (en) * 1998-07-10 2000-11-14 Shaklee Corporation Stable topical ascorbic acid compositions
DE19925499A1 (en) * 1999-06-04 2000-12-07 Beiersdorf Ag Use of ascorbic acid and one or more flavone derivatives and / or flavonone derivatives, in particular flavonoids, for the preparation of cosmetic or dermatological preparations for the prophylaxis or relief of sunburn
US6087393A (en) * 1999-06-10 2000-07-11 Igen, Inc. Stabilized vitamin C formulations
WO2001003664A1 (en) * 1999-07-08 2001-01-18 International Flora Technologies, Ltd. Stabilized ascorbic acid, composition, and method of use
US6190645B1 (en) 1999-07-15 2001-02-20 Playtex Products, Inc. Sunscreen for the scalp hair and hair
FR2800073B1 (en) * 1999-10-26 2001-11-23 Oreal NOVEL SILICATED COMPOUNDS DERIVED FROM ASCORBIC ACID, PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING SAME AND USES THEREOF
AU2001247264B2 (en) * 2000-03-03 2005-08-18 Australian Importers, Ltd. Micronized vitamin C formulation
US7101563B1 (en) * 2000-03-03 2006-09-05 Australian Importers, Ltd. Micronized vitamin C formulation
WO2002015860A1 (en) * 2000-08-24 2002-02-28 Tim Ioannides Topical antioxidant having vitamin c and method of combination with topical agent by user
US6830746B2 (en) 2001-09-21 2004-12-14 Playtex Products, Inc. Sunscreen compositions
DE10158447B4 (en) * 2001-11-30 2005-02-10 Aquanova German Solubilisate Technologies (Agt) Gmbh Ascorbic Solubilisate
KR20030048725A (en) * 2001-12-13 2003-06-25 바이오스펙트럼 주식회사 Production of stabilized ascorbic acid capsules and its use for cosmetics
US7314634B2 (en) * 2002-02-22 2008-01-01 Steven Hernandez Use of polyphenols to treat skin conditions
KR100477716B1 (en) * 2002-03-19 2005-03-18 바이오스펙트럼 주식회사 Method for producing a cosmetic composition containing L-ascorbic acid
US20040034094A1 (en) * 2002-08-16 2004-02-19 Gupta Shyam K. Vitamin C stabilized topical formulation
US7419655B2 (en) * 2002-09-11 2008-09-02 Kimberly-Clark Worldwide, Inc. Skin care products
US20040067890A1 (en) * 2002-10-04 2004-04-08 Gupta Shyam K. Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions
KR20040040557A (en) * 2002-11-07 2004-05-13 나드리화장품주식회사 Cosmetics composition having anti-wrinkle and anti-aging effect
US20120225107A1 (en) * 2011-03-04 2012-09-06 Caridad Hechavarria Stable skin and scar treatment composition
US10098832B1 (en) * 2017-03-31 2018-10-16 L'oreal Compositions for short and long term benefits for minimizing wrinkles and fine lines
CN117157047A (en) * 2021-03-30 2023-12-01 莱雅公司 Composition for caring keratin materials

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938969A (en) * 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938969A (en) * 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US20080292668A1 (en) * 2005-07-08 2008-11-27 Beatrice Baars Water-Free Cosmetic Preparation
US9192557B2 (en) * 2005-07-08 2015-11-24 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Water-free cosmetic preparation
US20070077261A1 (en) * 2005-10-03 2007-04-05 Jerry Zhang Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080312169A1 (en) * 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090197819A1 (en) * 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090232750A1 (en) * 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8760906B2 (en) 2009-11-24 2014-06-24 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor memory device
US9812179B2 (en) 2009-11-24 2017-11-07 Ovonyx Memory Technology, Llc Techniques for reducing disturbance in a semiconductor memory device
WO2014188276A2 (en) 2013-04-22 2014-11-27 Neocutis Sa Antioxidant compositions and methods of using the same
US9713604B2 (en) 2013-04-22 2017-07-25 Anteis Sa Antioxidant compositions and methods of using the same
US20180071205A1 (en) * 2014-12-08 2018-03-15 Jeane Disalvo Stable Vitamin C System
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
CA2251414A1 (en) 2000-04-16
KR20000026159A (en) 2000-05-15
US5843411A (en) 1998-12-01
AU8945598A (en) 2000-05-04

Similar Documents

Publication Publication Date Title
USRE38623E1 (en) Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US6110477A (en) Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US5153230A (en) Topical skin cream composition
US6146664A (en) Stable topical ascorbic acid compositions
US6572868B1 (en) Restructuring complex for cosmetic compositions
EP0826366B1 (en) Cosmetic compositions containing hydroxy acid or retinoid
US5935588A (en) Stable W/O/W emulsion containing a water-sensitive cosmetic and/or dermatological active agent
DE4242876C2 (en) Cosmetic and / or dermatological preparations for the cosmetic and / or dermatological care of the skin and / or the skin appendages
EP0717983B1 (en) Cosmetic compositions containing betulinic acid
US4474763A (en) Skin preparation
RU2537235C2 (en) Mildly acting indelible compositions for skin care
KR100499294B1 (en) Topical Compositions Containing Whey Proteins
EP0956048B1 (en) Stable compositions containing a retinoid and an enzyme based antioxidant system
GB2259014A (en) Compositions containing flavonoids
JP2000095663A (en) Agent for external use containing plant extract
JPS6251608A (en) Improved moisture rising lotion
DE202015009464U1 (en) cosmetic compositions
WO2002015860A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
US4518614A (en) Cosmetic preparation
PL199392B1 (en) Dermatological composition
JP2001002559A (en) Turmeric acting as anti-inflammatory agent in composition containing hydroxy acid or retinoid
JPH06336419A (en) External agent for skin
Akhtar et al. Formulation and in-vivo evaluation of a cosmetic multiple emulsion containing vitamin C and wheat protein
KR20060020630A (en) Topical treatment of sebum related skin conditions
KR102022184B1 (en) Cosmetic compositions comprising ε-Poly-L-lysine

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: TOPIX PHARMACEUTICALS INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHAFFER, BURT;HERNANDEZ, STEVEN;REEL/FRAME:039102/0922

Effective date: 20160630

AS Assignment

Owner name: ARES CAPITAL CORPORATION, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNOR:TOPIX PHARMACEUTICALS INC.;REEL/FRAME:047372/0672

Effective date: 20181031